Travere Therapeutics, Inc. has grown revenue 70% a year over three years and 24% a year over five. Revenue growth, 3-year annual rate: +70% (Biotechnology median +17%). Revenue growth, 5-year rate: +24%, growth has picked up over the last three years. Years of annual history on file: 16, FY2010 to FY2025, as filed.

TVTXTravere Therapeutics, Inc.

Healthcare

$52.12+110% 1Y

$52.12

$23.9052 weeks$67.51

Is it growing?

Good

Growing: revenue growing +77% year on year and operating margin widening (+49.3 points).

2 good, 1 without data

Revenue trend+77% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +24% a year.

Margin direction+49.3 points operating

Trailing-twelve-month operating margin, -9.1% now against -58.4% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TVTX growing?

Travere Therapeutics, Inc. has grown revenue 70% a year over three years and 24% a year over five.

+70%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +24%
Revenue growth, 5-year rate · +70% over three · growth has picked up over the last three years
Years of annual history on file: 16
Years of annual history on file · FY2010 to FY2025, as filed

Details›